Saracatinib

Generic Name: Saracatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂ClN_₅O_₅

CAS Number: 379231-04-6

Unique Ingredient Identifier: 9KD24QGH76

Background: Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Rectum
Stage IV Rectal Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Adenocarcinoma of the Colon
Recurrent Colon Cancer

Interventions: Drug: saracatinib
Other: laboratory biomarker analysis

First Posted Date: 2006-11-10

Last Posted Date: 2019-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00397878

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy